Abstracts tagged "therapy and tocilizumab"

Abstract Number: 2754 • 2018 ACR/ARHP Annual Meeting
Comparison between Tocilizumab Prescribed As Monotherapy Versus Combined with Conventional Immunosuppressant Agents in Giant Cell Arteritis Patients
Monica Calderón Goercke¹, Diana Prieto Peña¹, Javier Loricera², Vicente Aldasoro³, Santos Castañeda⁴, Ignacio Villa-Blanco⁵, Alicia Humbría⁴, Clara Moriano Morales⁶, Susana Romero-Yuste⁷, Francisco Javier Narváez⁸, Catalina Gómez-Arango⁹, Eva Perez Pampín¹⁰, Rafael Melero¹¹, Elena Becerra-Fernández¹², Marcelino Revenga Martínez¹³, Noelia Álvarez-Rivas¹⁴, Carlos Galisteo¹⁵, Francisca Sivera¹⁶, Alejandro Olivé-Marqués¹⁷, Maria Concepcion Alvarez de Buergo¹⁸, Luisa Marena Rojas Vargas¹⁹, Carlos Fernandez-Lopez²⁰, Francisco Navarro²¹, Enrique Raya Álvarez²², Eva Galindez-Agirregoikoa²³, Beatriz Arca²⁴, Roser Solans²⁵, Arantxa Conesa²⁶, Cristina Hidalgo-Calleja²⁷, Carlos Vázquez²⁸, Pau Lluch²⁹, Jose Andrés Román Ivorra³⁰, Sara Manrique-Arija³¹, Paloma Vela³², Eugenio De Miguel³³, Carmen Torres-Martín³⁴, Juan Carlos Nieto³⁵, Carmen Ordas-Calvo³⁶, Eva Salgado-Pérez³⁷, Cristina Luna Gómez³⁸, Francisco J. Toyos Sáenz de Miera³⁹, Nagore Fernandez-Llanio Cornella⁴⁰, Antonio García⁴¹, Carmen Larena⁴², Belén Atienza-Mateo⁴³, José Luis Martín-Varillas⁴³, Natalia Palmou-Fontana⁴³, Vanesa Calvo-Río⁴³, Carmen González-Vela⁴⁴, Alfonso Corrales⁴³, María Varela-García⁴⁵, Elena Aurrecoechea⁴⁶, Raquel Dos Santos⁴⁷, Angel García-Manzanares¹², Norberto Ortego Centeno⁴⁸, Sabela Fernández⁴⁹, Francisco Ortiz-Sanjuán⁵⁰, Montserrat Corteguera³⁴, Miguel Angel González-Gay⁴³, José Luis Hernández² and Ricardo Blanco⁴³, ¹Rheumatology, Rheumatology. Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ²Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ³Hospital Alto Deba. Mondragón. Spain, Mondragon, Spain, ⁴Rheumatology, Hospital La Princesa. Madrid. Spain, Madrid, Spain, ⁵Hospital de Sierrallana. Torrelavega. Spain, Torrelavega, Spain, ⁶Rheumatology, Complejo Asistencial Universitario de León. León. Spain, León, Spain, ⁷Hospital de Pontevedra. Spain, Pontevedra, Spain, ⁸Rheumatology Department, Hospital de Bellvitge. Barcelona. Spain, L’Hospitalet de Llobregat, Spain, ⁹Hospital Alto Deba, Mondragón. Spain, Mondragón, Spain, ¹⁰Rheumatology Division. Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain, ¹¹Rheumatology, Complexo Hospitalario Universitario de Vigo, Vigo. Spain, Vigo, Spain, ¹²Hospital Universitario de Torrevieja, Alicante. Spain, Alicante, Spain, ¹³Hospital Universitario Ramón y Cajal. Madrid. Spain, Madrid, Spain, ¹⁴Hospital Universitario Lucus Augusti, Lugo. Spain, Lugo, Spain, ¹⁵Rheumatology, Hospital Parc-Taulí, Sabadell, Spain, ¹⁶Rheumatology, Hospital General Universitario de Elda. Comunidad Valenciana. Spain, Elda, Spain, ¹⁷Rheumatology, Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ¹⁸Rheumatology, Hospital Río Carrión. Palencia. Spain, Palencia, Spain, ¹⁹Rheumatology Department, Hospital General La Mancha Centro, Alcázar de San Juan, Spain, ²⁰Servicio de Reumatología, Complexo Hospitalario Universitario de A Coruña (CHUAC), A Coruña. España, A Coruña, Spain, ²¹Hospital General Universitario de Elche, Alicante. Spain, Alicante, Spain, ²²Rheumatology, Hospital Universitario San Cecilio. Granada. Spain, Granada, Spain, ²³Rheumatology, University Hospital of Basurto, Bilbao, Spain, ²⁴Hospital Universitario San Agustín, Avilés. Spain, Avilés, Spain, ²⁵Autoimmune Systemic Diseases Unit, Department of Internal Medicine, Hospital Vall d'Hebron, Autonomous University of Barcelona, Spain, Barcelona, Spain, ²⁶Rheumatology, Hospital Clínico Universitario de Valencia. Spain, Valencia, Spain, ²⁷Rheumatology, Hospital Clínico Universitario de Salamanca, Salamanca. Spain, Salamanca, Spain, ²⁸Hospital Miguel Servet, Zaragoza. Spain, Zaragoza, Spain, ²⁹Rheumatology, Hospital Mateu Orfila. Menorca. Spain, Menorca, Spain, ³⁰Hospital La Fe. Valencia. Spain, Valencia, Spain, ³¹Medicine, University of Málaga, MÁLAGA, Spain, ³²Reumatología, Hospital General Universitario Alicante, Alicante, Spain, ³³Rheumatology, University Hospital La Paz, IdiPaz, Madrid, Spain, ³⁴Complejo Asistencial de Ávila, Ávila. Spain, Ávila, Spain, ³⁵Rheumatology, Hospital General Universitario Gregorio Marañón, Madrid, Spain, ³⁶Hospital Cabueñes, Gijón. Spain, Gijón, Spain, ³⁷Rheumatology, Complejo Hospitalario Universitario de Ourense, Ourense. Spain, Ourense, Spain, ³⁸Rheumatology, University Hospital Ntra. Sra. de La Candelaria, Santa Cruz de Tenerife, Spain, ³⁹Hospital Virgen de La Macarena. Sevilla. Spain, Sevilla, Spain, ⁴⁰Rheumatology Section. Hospital Arnau de Vilanova, Valencia, Spain, ⁴¹Hospital Unviersitario Virgen de las Nieves, Granada. Spain, Granada, Spain, ⁴²Hospital General Universitario Gregorio Marañón, Madrid, Spain, ⁴³Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ⁴⁴Pathology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ⁴⁵Complejo Hospitalario de Navarra, Navarra, Spain, ⁴⁶Rheumatology, Hospital de Sierrallana. Torrelavega. Spain, Torrelavega, Spain, ⁴⁷Complejo Hospitalario Universitario de Santiago. Spain, Santiago de Compostela, Spain, ⁴⁸Medicine Department, Hospital Universitario San Cecilio. Granada. Spain, Granada, Spain, ⁴⁹Rheumatology, Hospital Universitario San Agustín, Avilés. Spain, Avilés, Spain, ⁵⁰Rheumatology, Hospital La Fe. Valencia. Spain, Valencia, Spain
Background/Purpose: Giant cell arteritis (GCA) can be refractory to corticosteroid therapy (1-3). Tocilizumab (TCZ) has been approved in the treatment of GCA. There are no…
Abstract Number: 1436 • 2017 ACR/ARHP Annual Meeting
Therapeutic Drug Monitoring on Rheumatoid Arthritis Patients with Reduced Doses of Intravenous Tocilizumab
Virginia Ruiz-Esquide¹, Carla Bastida², Mariona Pascal³, Jordi Yagüe³, Dolors Soy² and Raimon Sanmartí¹, ¹Rheumatology Service, Hospital Clínic de Barcelona, Barcelona, Spain, ²Pharmacy Service, Hospital Clínic de Barcelona, Barcelona, Spain, ³Immunology Service, Hospital Clínic de Barcelona, b, Spain
Background/Purpose: Tocilizumab (TCZ) is an effective treatment for rheumatoid arthritis (RA). There is great variability in intravenous (iv) TCZ serum concentrations among individuals. Moreover, initial…
Abstract Number: 977 • 2016 ACR/ARHP Annual Meeting
Tocilizumab As an Add-on Therapy to Glucocorticoids during the First 3 Months of Treatment of Giant Cell Arteritis: Results of a French Multicenter Prospective Open-Label Study
Maxime Samson¹, Hervé Devilliers², Kim Heang Ly³, Francois Maurier⁴, Boris Bienvenu⁵, Benjamin Terrier⁶, Pierre Charles⁷, Jean-François Besancenot², Anne-Laure Fauchais⁸, Christine Binquet⁹, Sylvain Audia¹⁰ and Bernard Bonnotte¹, ¹Department of Internal Medicine and Clinical Immunology, Hôpital François Mitterrand, CHU de Dijon, Dijon, France, ²Department of Internal Medicine and Systemic Diseases, Hôpital François Mitterrand, CHU de Dijon, Dijon, France, ³Internal Medicine, University Hospital of Limoges, Limoges, France, ⁴Department of Internal Medicine, HP Metz Belle Isle Hospital, Metz, France, ⁵Caen University Hospital, Caen, France, ⁶Internal Medicine, Cochin University Hospital, Paris, France, ⁷Department of Internal Medicine, Institut Mutualiste Montsouris, Paris, France, ⁸Department of Internal Medicine, CHU de Limoges, Limoges, France, ⁹INSERM, CIC 1432, Clinical Epidemiology Unit, Hôpital François Mitterrand, CHU de Dijon, Dijon, France, ¹⁰Department of Internal Medicine and Clinical Immunology, Hôpital François Mitterrand, CHU de Dijon; INSERM, UMR1098, University of Bourgogne Franche-Comté, FHU INCREASE, Dijon, France
Background/Purpose: Giant cell arteritis (GCA) is a large-vessel vasculitis usually treated with glucocorticoids (GC). GC are effective but responsible for substantial morbidity and mortality. Tocilizumab…
Abstract Number: 2383 • 2013 ACR/ARHP Annual Meeting
A Useful Mathematical Model Able To Predict The Early Response To Tocilizumab In Rheumatoid Arthritis
Chiara Stagnaro¹, Claudia Ferrari², Rosaria Talarico³, Camillo Giacomelli¹, Stefano Bombardieri¹ and Laura Bazzichi¹, ¹University of Pisa, Rheumatology Unit, Pisa, Italy, ²Rheumatology Unit, University of Pisa, Pisa, Italy, ³Rheumatology Unit, Pisa, Italy
Background/Purpose: In the last few year the introduction of biological agents has radically changed the clinical outcome of patients with Rheumatoid Arthritis (RA). However, no…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].